R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) (@rbryanbell) 's Twitter Profile
R. Bryan Bell, MD, DDS, FACS, FRCS(Ed)

@rbryanbell

Cancer Institute Director. Head & Neck Surgeon. Clinical Researcher focused on #immunotherapy. Relentlessly working to #FinishCancer @Providence Tweets my own

ID: 4447438632

linkhttps://oregon.providence.org/our-services/p/providence-cancer-center/ calendar_today04-12-2015 00:56:17

3,3K Tweet

2,2K Takipçi

668 Takip Edilen

R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) (@rbryanbell) 's Twitter Profile Photo
R. Bryan Bell, MD, DDS, FACS, FRCS(Ed)
@rbryanbell

2 months ago

Adjuvant Cemiplimab better than Placebo in High-Risk Cutaneous SCC, giving more options for patients. Given that KN630 was negative in a similar, but not identical study group (c-post has higher risk pts), an important lesson in trial design. ⁦NEJM⁩ nejm.org/doi/full/10.10…